ALKEM LABORATORIES LTD. LAUNCHES NEUCENO FOR PARTIAL-ONSET SEIZURES

• Alkem Laboratories announced the launch of NeuCeno (cenobamate), an anti-seizure medication for partial-onset seizures in adult patients. • NeuCeno is a once daily oral therapy available in 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg and 200 mg tablets. • In clinical studies, adjunctive cenobamate produced up to 78% reduction in seizure frequency. • This launch represents an advancement in epilepsy management, addressing a significant healthcare burden in India.

Alkem Laboratories Limited

Open attachment

← Back to feed